Dr. Ragupathy ‘Madi’ Madiyalakan, Ph.D., CEO
Dr. Madiyalakan is the CEO and director of OncoQuest since its inception. He has also been the CEO of Quest PharmaTech since August, 2006; and Director since July, 2004. He was one of the founders of SonoLight Pharmaceuticals Corp. (served as its CEO and Director), CanBiocin Inc. (served as President, CEO and Director) and AltaRex Corp. (served as Vice-President, Planning and Chief Scientific Officer). Between 1987 and 1995 Dr. Madiyalakan served in various senior positions at Biomira Inc. Dr. Madiyalakan holds a Masters (Chemistry) and Ph.D. (Biochemistry) and a Certificate in Management Development. In addition, he has over 35 years of academic and industrial research experience on an international basis. He has published extensively and been an inventor of a number of patents.
Mr. Hany Awadalla, MBA, Senior Vice President and Chief Financial Officer
Mr. Awadalla has spent almost 30 years in healthcare investment banking at Merrill Lynch, UBS, and serving as Head of Healthcare M&A at Robertson Stephens and Wells Fargo and Head of Healthcare Investment Banking at Unterberg Towbin. Most recently and for the past 6 years, he served as Managing Director at National Securities. He has advised on over $15 billion of financing and M&A transactions in the healthcare sector. He received his MBA in Finance and MA in International Studies from the Wharton School
and the University of Pennsylvania, respectively and his BA from Columbia University.
Thomas Woo, M.Sc., Vice President of Product Development
As the Vice President of Product Development, Mr. Woo is focusing on process, formulation and clinical development for Quest’s products. Mr. Woo has been involved in successful clinical trial applications for more than six drug candidates, during his tenure at Cytovax Biotechnologies Inc., AltaRex Corp., Biomira Research Inc., and Biomira Inc. Mr. Woo holds a Bachelor of Science degree in Pharmacy and a Master of Science degree in Pharmaceutical Sciences from the University of Alberta.
Pierre Vermette, C.P.A., Chief Financial Officer
Pierre Vermette brings to OncoQuest Inc. experience in the areas of securities regulation, corporate governance and financial reporting. Prior to his employment with Quest he was employed for more than 11 years with the Alberta Securities Commission as a Securities Analyst, where he worked in Continuous Disclosure and Corporate Finance. Prior to that, he was employed as a Staff Accountant with MacKay & Partners, Chartered Accountants and Ernst & Young LLP.
Sean Du, MD, Senior Director of Clinical Affairs
Dr. Sean Du had an MD, and hold a bachelor degree in biochemistry followed by graduate degree received both in clinical research and experimental medicine from McGill University. Sean had 8 years of experience as medical doctor, and over 10 years of experience working on oncology clinical research with varieties of functions gained from university medical health center, CRO, Pharma, and biotech company, including basic medical research, clinical medicine, strategy development of new drugs, protocol design/development, and trials management etc. In recent years, Sean has been closely involved in new drug development of early phase in targeted therapy and immunotherapy, including anti-PD1 antibody, PARPi, BRAFi, BTKi, VEGFRi, EGFRi, METi, SYKi etc.
Dr. Eric Shi, CEO Oncovent – Senior Advisor to Oncoquest
Dr. Shi is a biomedical scientist specializing in cancer research and translational medicine development. Dr. Shi was the associate professor and then full Professor of Albert Einstein College of Medicine between 1994 - 2010, during which he led twelve national research programs funded by the U.S. National Cancer Institute (NCI) and U.S. Department of Defense (DOD). In 2010, Dr. Shi returned to China and became Vice President of the Academy of Clinical Research and Translational Medicine, Jiangsu Province. Dr. Shi leads three research projects sponsored by the China National Science Foundation, and one cancer early diagnosis research project sponsored by the National Key Technology R&D Program for the 12th Five-year Plan of China. In addition to his accomplishments in research and development, Dr. Shi is an entrepreneur. He is the founder of several Bio-medical companies, including two most recent ones: Dawei BioPharma in China, a medical device company specializing on the urinary tract system, and J&Q Diagnosis in China, a medical diagnosis company building a platform of metabolomics focusing on sex hormone metabolism. Upon graduation from Peking University School of Medicine in 1983, Dr. Shi was admitted to Dartmouth Medical School after passing the CUSBEA (China-U.S. Biochemistry Examination Application). Dr. Shi received his Ph.D. in biochemistry in 1989 at Dartmouth.
Dr. Chris Nicodermus, - Senior Advisor to OncoQuest
Dr. Nicodermus is Founder, President and Chief Scientific Officer of AIT Strategies. He served as Chairman and Chief Scientific Officer of Advanced Immune Therapeutics, Inc., from 2008-2012. Dr. Nicodemus received undergraduate training at Harvard College and received his MD degree Upstate Medical University in Syracuse, NY. He trained in Internal Medicine and completed a Research and Clinical fellowship in the laboratory of K Frank Austen, Department of Rheumatology and Clinical Immunology at Brigham and Women’s Hospital, Harvard Medical School, Boston. He held various research and clinical appointments at Harvard while pursuing a career in biotechnology. He has held executive positions at Pfizer, ImmuLogic, Diatide, AltaRex, United Therapeutics and Advanced Immune Therapeutics, Inc. He is a member of Alpha Omega Alpha and a fellow of the American College of Physicians.
Mrs. Connie Sykes – Regulatory Consultant
Mr. Connie Sykes is a principal consultant at EGA BioSciences. She has more than twenty years’ experience assisting pharmaceutical, biotechnology, nutraceutical, radiopharmaceutical, and medical device organizations.